11
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Failure of mycophenolate mofetil therapy in primary refractory nephrotic syndrome.

      Journal of nephrology
      Adult, Anti-Inflammatory Agents, Non-Steroidal, administration & dosage, adverse effects, Drug Resistance, Humans, Male, Middle Aged, Mycophenolic Acid, analogs & derivatives, Nephrotic Syndrome, drug therapy, Proteinuria, Time Factors

      Read this article at

      ScienceOpenPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Mycophenolate mofetil (MMF) has been suggested as a promising therapeutic agent in the treatment of idiopathic nephrotic syndrome. Two patients with persistent nephrotic syndrome, secondary to minimal change disease and idiopathic membranous nephropathy, respectively, who were steroid-, cyclophosphamide- and cyclosporine-resistant, were treated with MMF during a 6-12-month period. In these cases there was no beneficial effect from treatment with MMF. Therapy was stopped after 6 months in case 1 and after 12 months in case 2 due to the persistence of proteinuria.

          Related collections

          Author and article information

          Comments

          Comment on this article